INTRODUCTION
============

Pancreatic ductal adenocarcinoma (PDA) is an aggressive carcinoma whose incidence and prevalence have steadily increased over the years. As a result, PDA has become the fourth most common cause of cancer-related death in the western world [@b1-cln_71p315]. Pancreatic cancer is also the fourth leading cause of cancer-related mortality in the United States, and in Brazil, the five-year actuarial survival rate is 5% [@b2-cln_71p315]. The annual death rate from the disease almost equals its annual incidence due to the aggressive nature of the cancer and the lack of effective means of screening for it during its early, curable stage. Molecular markers and imaging have not proven to be accurate modalities for screening for pancreatic cancer. The diagnosis and management of pancreatic cancer continues to be an overwhelming challenge [@b3-cln_71p315],[@b4-cln_71p315].

Surgical treatment of PDA is considered a gold standard procedure as staging permits, but the large majority of patients have tumors that are unresectable at the time of diagnosis. Nevertheless, in the absence of credible alternative cures, surgical resection remains the only option with any potential for curing pancreatic adenocarcinoma, with overall resectability rates ranging from 15% to 20% for all patients, mortality rates ranging from 2 to 5% and total complication rates ranging from 30 to 40% [@b5-cln_71p315]\</underline\>.

Angiogenesis is the formation of new blood vessels from a pre-existing vascular network. During the prognostic state of cancer, it has been suggested that oxygen must penetrate 200 µm from a blood vessel to support cell existence and that neovascularization is mandatory for tumor cell survival [@b6-cln_71p315]. Some studies [@b7-cln_71p315],[@b8-cln_71p315] have correlated microvessel density (MVD) to angiogenesis and the presence of metastasis in the peripheral regions of pancreatic tumors. The p53 tumor suppressor gene seems to regulate angiogenesis to some extent, and p53 mutations have been reported as possible markers for identifying precursor lesions with malignant transformation potential.

The aim of the current study was to determine what type of relationship exists between MVD and p53 expression with respect to patient outcome following surgical treatment of pancreatic adenocarcinoma. Furthermore, we assessed the correlation between clinicopathological features, MVD and survival outcome in these patients.

SUBJECTS AND METHODS
====================

This study was approved by the Research and Ethics Committee of the Faculdade de Medicina da Universidade de São Paulo. Forty-nine patients underwent duodenopancreatectomy with lymphadenectomy and histologically proven pancreatic adenocarcinomas were selected. All patients were surgically treated at the Department of Digestive Surgery, São Paulo School of Medicine and did not receive chemotherapy or anti-angiogenesis therapy before surgery. All patients were followed up and data were collected between 2008 and 2012. The cases included 22 males and 27 females, with a mean age of 58.3 years ([Table 1](#t1-cln_71p315){ref-type="table"}). Paraffin blocks containing fragments of tumor and adjacent epithelia were sectioned, stained with hematoxylin & eosin (H&E), and prepared for histological analysis by light microscopy.

Immunohistochemical determination of p53 expression
---------------------------------------------------

Paraffin-embedded tissues were used for immunohistochemical analysis of p53 expression. First, sections (2-3 μm) were mounted on microscope slides. Then, the sections were deparaffinized in xylene at 60^o^ C for 30 minutes, followed by treatment with a graded series of alcohol and rehydration. For the deparaffinization, the samples were incubated with hydrogen peroxide in methanol for 20 min to block endogenous peroxidase. The sections were microwaved twice at 500 W for 5 min each time in 10 mmol/L sodium citrate (pH 6.0). The sections were then incubated with antibody against human p53 protein produced from the K0680 clone (DAKO LSAB®) and washed with phosphate-buffered saline (PBS).

The slides were examined by investigators who were blinded to the corresponding clinicopathologic data. p53 immunoreactivity was assessed as positive only when tumors exhibited intense nuclear staining and the reactivity was categorized as either negative expression (less than 10% positive tumor cells) or positive expression (at least 10% positive tumor cells).

Quantification of microvessel density
-------------------------------------

To quantify microvessel density (MVD) in sections stained for CD34, entire tumor sections were scanned at low power (40x magnification) to identify areas rich in microvessels, which were then counted in ten randomized areas ([Figure 1](#f1-cln_71p315){ref-type="fig"}). In each area, individual microvessels were counted under high power (200x magnification) to obtain a vessel count for a hundred randomized defined points. The average vessel count in the 10 randomized areas was taken as the MVD. The vessel count was considered significant when the reticulum was in the same position as the stained endothelial cells.

Associations with clinicopathological factors
---------------------------------------------

We next studied the associations between MVD and the following clinicopathological factors: sex, age (52 years old), staging, tumor size, histological type, vascular invasion, margins and survival rates. We also assessed the relationship between p53 expression and the same clinicopathological factors. Finailly, we compared the associations identified for MVD and p53.

Statistical methods
-------------------

The univariate association between MVD and each clinicopathological item was analyzed using chi-squared tests and t-tests. To determine independent prognostic factors, a generalized linear model was used. Kaplan-Meyer and Log-Rank tests were applied to assess survival rate. *P*\<0.05 was considered statistically significant.

RESULTS
=======

Of the 49 patients included in the study, forty-six had cephalic pancreatic carcinoma (93.8%). Thirty-one patients (63.2%) were at least stage IIB and 32 (65.3%) patients had tumors that were pT3. Twenty-nine patients (59.2%) had lymph node metastasis, 45 (91.8%) had perineural invasion and 26 (53.1%) had vascular invasion. The average tumor size was 3.36 cm (1.5 to 6.5 cm).

The mean MVD was 46.2 vessels/mm^2^, and this value was markedly higher in tumors equal to or greater than 3.0 cm in diameter (*p*=0.03) ([Table 2](#t2-cln_71p315){ref-type="table"}).

[Table 3](#t3-cln_71p315){ref-type="table"} shows the relationships that were identified between p53 and clinicopathological factors; however, no correlations were found.

The generalized linear model analysis of the assessed clinicopathological factors revealed that surgical margin was the only independent factor related to DMV (*p*\<0.05).

The actuarial survival rate did not demonstrate any statistically significant differences when compared to the MVD (*p*=0.69) ([Figure 2](#f2-cln_71p315){ref-type="fig"}).

DISCUSSION
==========

In 1971, Folkman formulated the hypothesis that angiogenesis in tumor specimens can be determined by the numbers and structures of blood vessels associated with a tumor and depends on neovascularization, which it is closely associated with tumor growth, staging and prognosis [@b9-cln_71p315],[@b10-cln_71p315]. In the same way, knowledge regarding the biomolecular mechanisms underlying angiogenesis has enabled efficient inhibition of this process using anti-angiogenic molecules.

Several studies demonstrated that angiogenesis precedes tumor progression and depends on a switch from a pre-vascular to a vascular phase. Recent works have shown that angiogenic factors are already expressed by pre-invasive lesions and the induction of angiogenesis is completed during the transition from hyperplasia to neoplasia. This phenomenon is important for invasive cancer screening in high-risk patients. Angiogenesis is also an important aspect of drug delivery for several tumor types [@b11-cln_71p315],[@b12-cln_71p315].

Our study indicated that MVD is not correlated with survival prognosis in PDA, a finding that is concordant with results reported by Ellis et al. [@b13-cln_71p315] and Karademir et al. [@b14-cln_71p315]. This result likely arose because of the absence of patient selection criteria and the different methodological methods applied (e.g., for vessel counting; [Table 4](#t4-cln_71p315){ref-type="table"}), resulting in diverse MVD values.

In contrast, late diagnosis of tumors and the use of surgical treatment have resulted in advanced staging of PDA. These processes allowed a large number of microvessels to be identified during tumor analysis and this MVD could not be differentiated between groups. Kuehn et al. [@b15-cln_71p315] demonstrated that a correlation exists between MVD and prognosis; however, over 60% of the patients studied were stage I and therefore had sparser MVD compared to those with advanced tumors.

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer. p53 mutations play a role in determining tumor sensitivity to apoptosis-inducing treatments, such as radiation or cytotoxic drugs [@b16-cln_71p315],[@b17-cln_71p315]. p53 protein has various important functions in cellular integration, including cell growth control, response to DNA damage, cell-cycle checkpoint control, regulation of transcription and control of genomic stability. It has been suggested that p53 protein may play a role in suppressing angiogenesis [@b18-cln_71p315]. However, in our study, no relationship was identified between p53 and MVD or clinicopathological factors. Overall, MVD analysis can be a useful tool for patient selection when studying angiogenesis inhibition [@b12-cln_71p315],[@b19-cln_71p315].

In conclusion, our results demonstrate that MVD is higher in tumors greater than 3.0 cm in diameter and in cases with involved margins. Furthermore, no relationship was found to exist between p53 expression and tumor angiogenesis, MVD or survival rates. Finally, neither MVD nor p53 expression could predict survival in patients with pancreatic adenocarcinoma. There was also no correlation between p53 expression and intratumoral MVD. Finally, MVD analysis is useful for predicting margin involvement.
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###### 

Demographic and clinicopathologic distributions.

  Variable                                            N    \%
  --------------------- ----------------------------- ---- -------
  **Gender**                                               
                        Female                        27   55.1%
                        Male                          22   44.9%
  Age                                                      
                        Mean = 58.3 (40--77 months)        
  T                                                        
                        1                             5    10.2%
                        2                             8    16.3%
                        3                             32   65.3%
                        4                             4    8.2%
  N                                                        
                        Negative                      20   40.8%
                        Positive                      29   59.2%
  Staging                                                  
                        IA                            4    8.2%
                        IB                            5    10.2%
                        IIA                           9    18.4%
                        IIB                           27   55.1%
                        III                           4    8.2%
  Perineural invasion                                      
                        Absent                        4    8.2%
                        Present                       45   91.8%
  Vascular invasion                                        
                        Absent                        23   46.9%
                        Present                       26   53.1%
  Size                                                     
                        Mean = 3.32 (1.5-6.5 cm)           
                        \<3.0 cm                      18   36.7%
                        ≥3.0 cm                       31   63.3%
  Histological type                                        
                        Well differentiated           23   46.9%
                        Moderately differentiated     19   38.8%
                        Undifferentiated              7    14.3%
  Margins                                                  
                        Free                          30   61.2%
                        Compromised                   19   38.8%
  Vascular resection                                       
                        No                            39   79.6%
                        Yes                           10   20.4%
  MVD                                                      
                        Mean                               
                        \<46.2                        28   57.1%
                        ≥46.2                         21   42.9%
  p53                                                      
                        Negative                      29   59.2%
                        Positive                      20   40.8%

###### 

Relationships between microvessel density and clinicopathological features.

                                                           No. patients   Mean MVD    *p*
  ------------------- ------------------------------------ -------------- ----------- ------
  **Total**                                                **49**         **46.2**    
  Age                                                                                 
                      \<52 years                           14 (28.6%)     47.9±16.9   0.62
                      ≥52 years                            35 (71.4%)     45.0±21.5   
  Gender                                                                              
                      Male                                 22(44.9%)      45.1±19.2   0.71
                      Female                               27(45.1%)      47.1±17.2   
  T                                                                                   
                      T1-2                                 13 (26.5%)     49.4±19.8   0.41
                      T3-4                                 36 (73.5%)     44.7±17.6   
  N                                                                                   
                      Negative                             20 (40.8%)     47.3±17.6   0.18
                      Positive                             29 (59.2%)     45.2±18.9   
  Size                                                                                
                      \<3.0 cm                             20 (40.8%)     39.2±13.3   0.03
                      ≥3.0 cm                              29 (59.2%)     50.4±19.8   
  Histological type                                                                   
                      Well and moderately differentiated   42 (85.7%)     44.7±17.2   0.05
                      Undifferentiated                     7 (14.3%)      55.3±12.5   
  p53                                                                                 
                      Negative                             29 (59.2%)     44.0±14.7   0.39
                      Positive                             20 (40.8%)     48.9±22.3   
  Vascular invasion                                                                   
                      Absent                               23 (46.9%)     46.1±18.3   0.99
                      Present                              26 (53.1%)     46.2±18.4   
  Margins                                                                             
                      Free                                 30 (61.2%)     42.5±15.6   0.04
                      Compromised                          19 (39.8%)     53.3±20.1   

###### 

Relationships between p53 expression and clinicopathological factors (no correlations were found).

                                                           p53 negative   p53 positive   *p*
  ------------------- ------------------------------------ -------------- -------------- ------
  Age                                                                                    
                      \<52 years                           7              7              0.52
                      ≥52 years                            22             13             
  Gender                                                                                 
                      Male                                 12             15             0.04
                      Female                               17             5              
  T                                                                                      
                      T1-2                                 9              4              0.21
                      T3-4                                 20             16             
  N                                                                                      
                      Negative                             11             9              0.77
                      Positive                             18             11             
  Size                                                                                   
                      \<3.0 cm                             11             9              0.77
                      ≥3.0 cm                              18             11             
  Histological type   Well and moderately differentiated   24             18             0.41
                      Undifferentiated                     5              2              
  Vascular invasion                                                                      
                      Absent                               14             9              1.0
                      Present                              15             11             
  Margins                                                                                
                      Free                                 19             11             0.55
                      Compromised                          10             9              

###### 

Different methods used to count vessels.

  Author           Year   Number of patients   Antibody              Number of areas   Type of count   MVD (vessels/mm^2^)
  ---------------- ------ -------------------- --------------------- ----------------- --------------- ------------------------------------------------
  Present study    2008   49                   CD34                  10                Weidner         46.2
  Takagi           2008   41                   CD34CD45Factor VIII   3                 Lúmem           
  Esposito         2004   137                  CD34                  5                 Weidner         101[\*](#tfn1-cln_71p315){ref-type="table-fn"}
  Nakagawa         2002   32                   CD34                  5                 Weidner         
  Niedergethmann   2002   70                   CD34                  5                 Weidner         85[\*](#tfn1-cln_71p315){ref-type="table-fn"}
  Karademir        2000   22                   Factor VIII           3                 Weidner         3.4\#
  Ikeda            1999   40                   CD34                  6                 Weidner         
  Fujimoto         1998   50                   CD34                  4                 Weidner         30.1
  Ellis            1998   22                   Factor VIII           \-                Weidner         44.9

Only evaluated hypervascularized areas of neoplasm.

\#Vessels/mm^2^/mm^3^ -- vessels/mm.
